The phase 3 portion of the trial will test safety and efficacy of a single intravenous infusion ... is based on a cocktail of two antibodies that neutralise the virus. Shares in Regeneron were ...
The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback